Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.00 | 0.01 | 0.09 |
| FCF Yield | -7.38% | -451.85% | -8.29% | 0.67% |
| EV / EBITDA | 0.00 | 0.00 | 5.41 | -0.80 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 16.76% | -19.27% |
| Gross Margin | 0.00% | 0.00% | -1,260.38% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.73 | 0.83 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -64.01% | -169.64% | -1,819.18% | 109.86% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 8.49 | 6.18 |
| Interest Coverage | 0.00 | 0.00 | -3.25 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1,180.38 | -161.64 |